MultiCell Technologies, Inc. has filed a U.S. patent application covering the design and therapeutic use of novel, next-generation antibody drug conjugates (ADCs) which provide for the simultaneous targeted delivery of multiple drugs from a single antibody. Cancer therapy often results in the patient becoming very sick due to toxicity and off-target effects of certain drugs used to treat patients. ADCs take advantage of the target specificity of a monoclonal antibody to deliver a potent cytotoxic compound selectively to just the targeted tumor cells, thus improving the drug's therapeutic safety window by decreasing the likelihood of adverse off-target effects.

As a result of decreasing off-target effects, overall patient experience and patient outcomes are improved. This patent application describes compositions-of-matter, a multivalent biodegradable linker and tether to attach drugs to the antibody or other targeting agents, and the therapeutic use of such drug conjugates to treat cancer and other diseases. These unique ADCs are designed to release drugs in their native form via biodegradation of the novel cleavable, multi-valent linker and tether after the ADC enters the cell.